Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
80,217
-
Share change
-
+29,466
-
Total reported value
-
$672,000
-
Price per share
-
$8.37
-
Number of holders
-
4
-
Value change
-
-$189,113
-
Number of buys
-
3
-
Number of sells
-
3
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q4 2019
As of 31 Dec 2019,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
4 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,217 shares.
The largest 4 holders included
ARK Investment Management LLC, RENAISSANCE TECHNOLOGIES LLC, UBS Group AG, and DEUTSCHE BANK AG\.
This page lists
4
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.